NEW YORK -- (BUSINESS WIRE) -- Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, is pleased to announce that Michelle Marlborough, the company’s vice president of product strategy, has been named by PharmaVOICE Magazine as one of the 100 most inspiring people in the life sciences industry.
Recently honored as a 2014 Rising Star by the Healthcare Businesswomen’s Association (HBA), Marlborough has been at the forefront of transforming clinical trials with innovative technology and analytics. She leads the Medidata team responsible for designing a platform of cloud-based solutions that is modernizing drug development, helping life sciences companies bring needed therapies to patients faster and with lower cost and risk.
"This recognition is a terrific reaffirmation of what we at Medidata already knew: Michelle has been instrumental to our success, and she is constantly pushing our industry to modernize drug development through the use of innovative technologies," said Glen de Vries, Medidata’s president. "Michelle's vision unifies the needs of our clients with data-driven analytics and the patient's voice. We are thrilled that PharmaVOICE agrees her contribution is worthy of praise."
With this honor, Marlborough becomes the ninth Medidata executive to be named to the PharmaVOICE 100, an annual list of individuals recognized for translating industry issues into opportunities and pioneering new paths to success for life sciences. Distinguished honorees represent a broad cross section of the industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, marketing, technology and many other sectors.
"Michelle is an industry thought leader and a passionate proponent of the role technology can play in improving clinical research,” said Taren Grom, editor of PharmaVOICE Magazine. “She truly understands the value technology brings to drug development and its potential to make clinical trials run better, smarter and safer. We are proud to include Michelle on this year's PharmaVOICE 100 list of the most inspiring leaders in the life sciences industry."
Connect with Medidata:
PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life sciences industry. PharmaVOICE reaches more than 29,000 subscribers every month in print and more than 100,000 readers through its online version, which contains original exclusive bonus content. PharmaVOICE’s unique horizontal editorial approach cuts industry silos, providing a holistic overview of the life sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships. PharmaVOICE's multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of life sciences business practices and topics.
About Medidata Solutions
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global clients, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.